JonesResearch analyst Justin Walsh lowered the firm’s price target on Theratechnologies to $3 from $6 and keeps a Buy rating on the shares post the Q2 report. The analyst removed potential risk-adjusted revenues in SORT1+ end-stage endometrial cancer following management comments that the primary focus for current development efforts will be on ovarian cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on THTX:
- Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates
- Theratechnologies sees FY23 revenue $82M-$87M, consensus $91.66M
- Theratechnologies reports Q2 revenue $17.549M, consensus $20.32M
- Theratechnologies assumed with a Hold at Canaccord
- Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
